Related Experiment Video
Updated: Jun 26, 2026
Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production
Published on: March 2, 2014
An attenuated lymphocytic choriomeningitis virus vector enhances tumor control in mice partly via IFN-I
Young Rock Chung1, Bakare Awakoaiye1, Tanushree Dangi1
1Department of Microbiology-Immunology, Feinberg School of Medicine, and.
Abstract:
Viral vectors are being used for the treatment of cancer. Yet, their efficacy varies among tumors and their use poses challenges in immunosuppressed patients, underscoring the need for alternatives. We report striking antitumoral effects by a nonlytic viral vector based on attenuated lymphocytic choriomeningitis virus (r3LCMV). We show in multiple tumor models that injection of tumor-bearing mice with this vector results in improved tumor control and survival. Importantly, r3LCMV improved tumor control in immunodeficient Rag1-/- mice and MyD88-/- mice, suggesting that multiple pathways contributed to the antitumoral effects. The antitumoral effects of r3LCMV were also observed when this vector was administered several weeks before tumor challenges, suggesting the induction of trained immunity. Single-cell RNA sequencing analyses, antibody blockade experiments, and knockout models revealed a critical role for host-intrinsic IFN-I in the antitumoral efficacy of r3LCMV vectors. Collectively, these data demonstrate potent antitumoral effects by r3LCMV vectors and unveil multiple mechanisms underlying their antitumoral efficacy.
Insights
A novel attenuated lymphocytic choriomeningitis virus (r3LCMV) vector shows potent anti-cancer effects. This viral vector demonstrates significant tumor control and improved survival across various models, even in immunodeficient mice.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Viral vectors are explored for cancer therapy, but efficacy is inconsistent and challenges exist in immunosuppressed patients.
- There is a critical need for alternative viral vector strategies with improved efficacy and broader applicability.
Purpose of the Study:
- To evaluate the antitumoral effects of a novel nonlytic viral vector, r3LCMV, in preclinical cancer models.
- To investigate the mechanisms underlying the observed antitumoral efficacy of r3LCMV.
Main Methods:
- Utilized multiple syngeneic tumor models in mice, including immunodeficient strains (Rag1-/-, MyD88-/-).
- Administered the r3LCMV vector and assessed tumor control, survival, and immune responses.
- Employed single-cell RNA sequencing, antibody blockade, and knockout models to elucidate mechanisms.
Main Results:
- r3LCMV demonstrated significant tumor control and improved survival in various tumor models.
- Antitumoral effects were observed in immunodeficient mice, indicating multiple contributing pathways.
- Evidence suggested the induction of trained immunity upon early administration of r3LCMV.
- Host-intrinsic Interferon-I (IFN-I) was identified as critical for r3LCMV's antitumoral efficacy.
Conclusions:
- The attenuated r3LCMV vector exhibits potent, broad-spectrum antitumoral effects.
- Multiple mechanisms, including host-intrinsic IFN-I signaling and potentially trained immunity, contribute to efficacy.
- r3LCMV represents a promising alternative viral vector for cancer treatment.
